The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer

Kirsty Ross; Emma Pailler; Vincent Faugeroux; Melissa Taylor; Marianne Oulhen; Nathalie Auger; David Planchard; Jean Charles Soria; Colin R. Lindsay; Benjamin Besse; Philippe Vielh; Françoise Farace

doi:10.1586/14737159.2015.1111139

The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer

Kirsty Ross, Emma Pailler, Vincent Faugeroux, Melissa Taylor, Marianne Oulhen, Nathalie Auger, David Planchard, Jean Charles Soria, Colin R. Lindsay, Benjamin Besse, Philippe Vielh, Françoise Farace

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

25 Citations (Scopus)

Résumé

In non-small-cell lung cancer (NSCLC), genotyping tumor biopsies for targetable somatic alterations has become routine practice. However, serial biopsies have limitations: they may be technically difficult or impossible and could incur serious risks to patients. Circulating tumor cells (CTCs) offer an alternative source for tumor analysis that is easily accessible and presents the potential to identify predictive biomarkers to tailor therapies on a personalized basis. Examined here is our current knowledge of CTC detection and characterization in NSCLC and their potential role in EGFR-mutant, ALK-rearranged and ROS1-rearranged patients. This is followed by discussion of the ongoing issues such as the question of CTC partnership as diagnostic tools in NSCLC.

langue originale	Anglais
Pages (de - à)	1605-1629
Nombre de pages	25
journal	Expert Review of Molecular Diagnostics
Volume	15
Numéro de publication	12
Les DOIs	https://doi.org/10.1586/14737159.2015.1111139
état	Publié - 2 déc. 2015

Accès au document

10.1586/14737159.2015.1111139

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{5e129fe38d1c4c49af52bd494b7587c5,

title = "The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer",

abstract = "In non-small-cell lung cancer (NSCLC), genotyping tumor biopsies for targetable somatic alterations has become routine practice. However, serial biopsies have limitations: they may be technically difficult or impossible and could incur serious risks to patients. Circulating tumor cells (CTCs) offer an alternative source for tumor analysis that is easily accessible and presents the potential to identify predictive biomarkers to tailor therapies on a personalized basis. Examined here is our current knowledge of CTC detection and characterization in NSCLC and their potential role in EGFR-mutant, ALK-rearranged and ROS1-rearranged patients. This is followed by discussion of the ongoing issues such as the question of CTC partnership as diagnostic tools in NSCLC.",

keywords = "ALK rearrangement, Circulating tumor cells, EGFR mutation, diagnostic biomarkers, non-small-cell lung carcinoma",

author = "Kirsty Ross and Emma Pailler and Vincent Faugeroux and Melissa Taylor and Marianne Oulhen and Nathalie Auger and David Planchard and Soria, {Jean Charles} and Lindsay, {Colin R.} and Benjamin Besse and Philippe Vielh and Fran{\c c}oise Farace",

note = "Publisher Copyright: {\textcopyright} 2015 Taylor & Francis.",

year = "2015",

month = dec,

day = "2",

doi = "10.1586/14737159.2015.1111139",

language = "English",

volume = "15",

pages = "1605--1629",

journal = "Expert Review of Molecular Diagnostics",

issn = "1473-7159",

number = "12",

}

TY - JOUR

T1 - The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer

AU - Ross, Kirsty

AU - Pailler, Emma

AU - Faugeroux, Vincent

AU - Taylor, Melissa

AU - Oulhen, Marianne

AU - Auger, Nathalie

AU - Planchard, David

AU - Soria, Jean Charles

AU - Lindsay, Colin R.

AU - Besse, Benjamin

AU - Vielh, Philippe

AU - Farace, Françoise

PY - 2015/12/2

Y1 - 2015/12/2

N2 - In non-small-cell lung cancer (NSCLC), genotyping tumor biopsies for targetable somatic alterations has become routine practice. However, serial biopsies have limitations: they may be technically difficult or impossible and could incur serious risks to patients. Circulating tumor cells (CTCs) offer an alternative source for tumor analysis that is easily accessible and presents the potential to identify predictive biomarkers to tailor therapies on a personalized basis. Examined here is our current knowledge of CTC detection and characterization in NSCLC and their potential role in EGFR-mutant, ALK-rearranged and ROS1-rearranged patients. This is followed by discussion of the ongoing issues such as the question of CTC partnership as diagnostic tools in NSCLC.

AB - In non-small-cell lung cancer (NSCLC), genotyping tumor biopsies for targetable somatic alterations has become routine practice. However, serial biopsies have limitations: they may be technically difficult or impossible and could incur serious risks to patients. Circulating tumor cells (CTCs) offer an alternative source for tumor analysis that is easily accessible and presents the potential to identify predictive biomarkers to tailor therapies on a personalized basis. Examined here is our current knowledge of CTC detection and characterization in NSCLC and their potential role in EGFR-mutant, ALK-rearranged and ROS1-rearranged patients. This is followed by discussion of the ongoing issues such as the question of CTC partnership as diagnostic tools in NSCLC.

KW - ALK rearrangement

KW - Circulating tumor cells

KW - EGFR mutation

KW - diagnostic biomarkers

KW - non-small-cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84949528831&partnerID=8YFLogxK

U2 - 10.1586/14737159.2015.1111139

DO - 10.1586/14737159.2015.1111139

M3 - Review article

C2 - 26564313

AN - SCOPUS:84949528831

SN - 1473-7159

VL - 15

SP - 1605

EP - 1629

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

IS - 12

ER -